U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07541001) titled 'Phase II Trial of PRL3-Zumab in Advanced Solid Tumor Patients' on April 15.
Brief Summary: This is a multicenter, Phase II, open-label, single-dose level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors.
The study consists of a screening period (Day -21 to Day -1, during which all screening assessments must be completed prior to the first administration of study treatment), a treatment period (study visits every 2 weeks), an End-of-Treatment (EOT) visit (to beconducted within 14 days after discontinuation of treatment for any reason), a safety follow up visit (30 days after the las...